DOI:
10.1055/s-00000075
Seminars in Respiratory and Critical Care Medicine
LinksClose Window
References
Gonem S, Berair R, Singapuri A. , et al.
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Lancet Respir Med 2016;
4 (09) 699-707
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.